| Withdrawn | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC NCT06592664 | Lisata Therapeutics, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers NCT06958224 | University Hospital, Lille | N/A |
| Not Yet Recruiting | IBI343 in Combination Therapy for Advanced Malignant Solid Tumors NCT07483554 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Recruiting | A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Ri NCT07324096 | Mayo Clinic | N/A |
| Recruiting | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications NCT07432633 | Blue Earth Diagnostics | Phase 1 / Phase 2 |
| Not Yet Recruiting | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patie NCT07219238 | GE Healthcare | Phase 2 / Phase 3 |
| Recruiting | Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy NCT07328607 | Minia University | N/A |
| Recruiting | Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer NCT07232810 | Minia University | N/A |
| Recruiting | Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment NCT06574620 | British Columbia Cancer Agency | N/A |
| Recruiting | Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer NCT07199764 | University of Pennsylvania | Phase 2 |
| Recruiting | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors NCT07261631 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination NCT07076121 | Bristol-Myers Squibb | Phase 2 / Phase 3 |
| Recruiting | A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Can NCT07024615 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Recruiting | TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC) NCT07284277 | Clinica Universidad de Navarra, Universidad de Navarra | Phase 1 / Phase 2 |
| Recruiting | Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas NCT07155525 | Minia University | Phase 3 |
| Recruiting | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection NCT06503146 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma NCT07096362 | University of Miami | Phase 2 |
| Recruiting | A Study of GV20-0251 in Advanced or Refractory Solid Tumors NCT07106827 | West China Hospital | Phase 1 |
| Recruiting | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors NCT07094204 | Astellas Pharma Inc | Phase 1 |
| Recruiting | PRetreatment MRI for OCcult Liver Metastasis Assessment In Pancreatic Ductal adenocarcinoMa NCT07252076 | Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria | — |
| Recruiting | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors NCT07020221 | Verastem, Inc. | Phase 1 / Phase 2 |
| Recruiting | Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinom NCT07163273 | Northwell Health | Phase 2 |
| Recruiting | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187 | Dren Bio | Phase 1 |
| Recruiting | Study for AZD4360 in Participants With Advanced Solid Tumours NCT06921928 | AstraZeneca | Phase 1 / Phase 2 |
| Recruiting | Lead-212 PSV359 Therapy for Patients With Solid Tumors NCT06710756 | Perspective Therapeutics | Phase 1 / Phase 2 |
| Recruiting | PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) NCT06673017 | PanTher Therapeutics | Phase 1 |
| Recruiting | A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or NCT06882746 | Boehringer Ingelheim | Phase 1 |
| Recruiting | Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectabl NCT06831136 | The University of Texas Health Science Center, Houston | Phase 2 |
| Active Not Recruiting | Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center NCT06712797 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Recruiting | Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibr NCT06782412 | KU Leuven | Phase 2 / Phase 3 |
| Recruiting | Reinforced Pancreaticojejunostomy With or Without glubran2 NCT06756074 | Minia University | Phase 2 |
| Not Yet Recruiting | Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Ch NCT05314998 | John Neoptolemos | Phase 3 |
| Recruiting | Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer NCT07226154 | City of Hope Medical Center | — |
| Active Not Recruiting | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors NCT06607185 | Eli Lilly and Company | Phase 1 |
| Terminated | A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Canc NCT06528093 | Boehringer Ingelheim | Phase 1 |
| Recruiting | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers NCT06562192 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer NCT06600906 | University of California, San Francisco | — |
| Recruiting | A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors NCT06598007 | Crossignal Therapeutics, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | The LINFU® U.S. Registry for the in the General Population Without Risk Factors NCT06276803 | Adenocyte, LLC | — |
| Recruiting | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors NCT06586515 | Eli Lilly and Company | Phase 1 |
| Recruiting | Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Anal NCT06549725 | Lipidica, a.s. | N/A |
| Active Not Recruiting | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Assoc NCT06115499 | Alliance for Clinical Trials in Oncology | Phase 2 / Phase 3 |
| Active Not Recruiting | Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma NCT06492915 | Chipscreen Biosciences, Ltd. | Phase 2 |
| Active Not Recruiting | AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC NCT05632328 | Bruno Bockorny | Phase 2 |
| Recruiting | AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort NCT06638866 | Changhai Hospital | — |
| Recruiting | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours NCT06147037 | AstraZeneca | Phase 1 |
| Active Not Recruiting | POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for Patients With Pancreat NCT06275737 | GERCOR - Multidisciplinary Oncology Cooperative Group | N/A |
| Recruiting | A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) NCT06428409 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Terminated | Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed Aft NCT06478862 | Lipomedix Pharmaceuticals Inc. | Phase 2 |
| Recruiting | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors NCT06445062 | Revolution Medicines, Inc. | Phase 1 / Phase 2 |
| Terminated | Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma NCT06122480 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Terminated | Ketamine-assisted Therapy for Advanced GI Cancer NCT06077487 | Brian Anderson, MD | Phase 4 |
| Terminated | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (M NCT06287463 | Deciphera Pharmaceuticals, LLC | Phase 1 |
| Recruiting | Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma NCT06048484 | Gulam Manji | Phase 2 |
| Recruiting | A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer NCT06079346 | Oncotelic Inc. | Phase 2 / Phase 3 |
| Not Yet Recruiting | PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study) NCT06345599 | Second Affiliated Hospital of Soochow University | Phase 1 / Phase 2 |
| Recruiting | A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours NCT06305247 | Ipsen | Phase 1 / Phase 2 |
| Recruiting | Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma. NCT07148830 | Minia University | N/A |
| Recruiting | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors NCT06218914 | AstraZeneca | Phase 1 |
| Active Not Recruiting | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Meta NCT06105021 | Affini-T Therapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery NCT06214533 | Sixth Affiliated Hospital, Sun Yat-sen University | N/A |
| Recruiting | French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC) NCT06287749 | University Hospital, Montpellier | — |
| Recruiting | Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma NCT06015724 | Georgetown University | Phase 2 |
| Enrolling By Invitation | Evaluating LINFU™: A Noninvasive Method for Collecting Pancreatic Cells for the Early Detection of Pancreatic NCT04793633 | Adenocyte, LLC | — |
| Active Not Recruiting | Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer NCT05634720 | Duke University | Phase 4 |
| Recruiting | AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinom NCT06320717 | Roswell Park Cancer Institute | — |
| Recruiting | NALIRIFOX as Induction Therapy in LAPC NCT06467565 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 NCT06219941 | AstraZeneca | Phase 2 |
| Active Not Recruiting | A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer NCT06168812 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach NCT06151691 | Fudan University | — |
| Recruiting | Durvalumab and Oleclumab in Resectable PDAC NCT06060405 | University Health Network, Toronto | Phase 2 |
| Recruiting | Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals NCT06122896 | Dana-Farber Cancer Institute | EARLY_Phase 1 |
| Recruiting | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Active Not Recruiting | ZN-c3 + Gemcitabine in Pancreatic Cancer NCT06015659 | Brandon Huffman, MD | Phase 2 |
| Recruiting | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced K NCT06128551 | Revolution Medicines, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors NCT05983133 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors NCT05799274 | Radiopharm Theranostics, Ltd | Phase 1 |
| Active Not Recruiting | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid NCT06084481 | AbbVie | Phase 1 |
| Terminated | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. NCT05977322 | Novartis Pharmaceuticals | Phase 1 |
| Active Not Recruiting | A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibit NCT05867121 | Genentech, Inc. | Phase 1 |
| Unknown | Venous Thromboembolism in Primary Pancreatic Tumour Resection NCT05964621 | University of Thessaly | — |
| Recruiting | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors NCT06005493 | AstraZeneca | Phase 1 / Phase 2 |
| Active Not Recruiting | Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) NCT05915351 | University of Kansas Medical Center | Phase 2 |
| Terminated | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors NCT05563272 | Telix Pharmaceuticals (Innovations) Pty Ltd | Phase 2 |
| Recruiting | A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PD NCT05851924 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer NCT05846516 | Boehringer Ingelheim | Phase 1 |
| Recruiting | Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations NCT06041009 | Qilu Hospital of Shandong University | — |
| Completed | Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers NCT05641896 | SOFIE | Phase 2 |
| Recruiting | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies NCT05783622 | Janux Therapeutics | Phase 1 |
| Active Not Recruiting | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors NCT05726864 | Elicio Therapeutics | Phase 1 / Phase 2 |
| Completed | Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarci NCT05546853 | University Hospital, Grenoble | Phase 1 |
| Recruiting | Pancreatic Cancer Detection Consortium NCT06388967 | City of Hope Medical Center | — |
| Recruiting | Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With NCT05482893 | Phanes Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer NCT05708599 | Boehringer Ingelheim | N/A |
| Withdrawn | PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers NCT05737615 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treate NCT05630989 | Mandana Kamgar, MD | — |
| Unknown | AMT-151 in Patients With Selected Advanced Solid Tumours NCT05498597 | Multitude Therapeutics Inc. | Phase 1 |
| Completed | Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma NCT05440942 | Peter Hosein, MD | Phase 1 |
| Unknown | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma NCT05955157 | University of Malaya | Phase 2 / Phase 3 |
| Completed | Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarc NCT06344299 | Fudan University | — |
| Not Yet Recruiting | Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer NCT05611359 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Unknown | Exploring the Application of 3D Bioprinting for Personalized Treatment in Pancreatic Ductal Adenocarcinoma NCT05955092 | Peking Union Medical College Hospital | — |
| Completed | Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC) NCT05727319 | NHS Greater Glasgow and Clyde | — |
| Unknown | Prognostic Value of Myosteatosis and Creatinine-to-cystatin C Ratio in Patients With Pancreatic Ductal Adenoca NCT05584852 | The Affiliated Hospital of Qingdao University | — |
| Active Not Recruiting | The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics NCT05692596 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Active Not Recruiting | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Sol NCT05462717 | Revolution Medicines, Inc. | Phase 1 |
| Active Not Recruiting | Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma NCT05209074 | Case Comprehensive Cancer Center | Phase 1 |
| Recruiting | Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic NCT05132504 | Baylor College of Medicine | Phase 2 |
| Recruiting | Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combinati NCT05431270 | Phanes Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer NCT05254171 | Panbela Therapeutics, Inc. | Phase 2 / Phase 3 |
| Terminated | Escitalopram to Placebo in Patients With Localized Pancreatic Cancer NCT05289830 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; NCT05432193 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Phase 1 |
| Completed | Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions NCT05476978 | Huazhong University of Science and Technology | — |
| Active Not Recruiting | A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarci NCT05336266 | Andrew Hendifar, MD | EARLY_Phase 1 |
| Recruiting | Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC) NCT05346536 | University Hospital, Montpellier | N/A |
| Active Not Recruiting | ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer NCT05355298 | Amplia Therapeutics Limited | Phase 1 / Phase 2 |
| Active Not Recruiting | The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreate NCT05042128 | Australasian Gastro-Intestinal Trials Group | Phase 2 |
| Completed | Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer NCT05303090 | Fudan University | Phase 1 |
| Recruiting | Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab NCT05257993 | Onconic Therapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer NCT05296421 | Rutgers, The State University of New Jersey | N/A |
| Completed | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid NCT05074472 | ZielBio, Inc. | Phase 1 / Phase 2 |
| Recruiting | Pancreatic Cancer Screening in a Population at High Risk NCT06330441 | Masaryk Memorial Cancer Institute | N/A |
| Recruiting | Fecal Microbial Transplants for the Treatment of Pancreatic Cancer NCT04975217 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Synergistic Immunomodulatory Effect of Synbiotics Pre and Postoperative Resection of Pancreatic Ductal Adenoca NCT06199752 | Theodor Bilharz Research Institute | Phase 4 |
| Completed | A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers NCT05031494 | Eucure (Beijing) Biopharma Co., Ltd | Phase 2 |
| Active Not Recruiting | Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer NCT05141643 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Recruiting | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119 | Children's Oncology Group | Phase 1 / Phase 2 |
| Recruiting | Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer NCT04146298 | Changhai Hospital | Phase 1 / Phase 2 |
| Recruiting | PHL Treatment in Pancreatic Cancer NCT05365893 | Fox Chase Cancer Center | EARLY_Phase 1 |
| Terminated | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. NCT04712721 | Novartis Pharmaceuticals | EARLY_Phase 1 |
| Active Not Recruiting | Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarc NCT04862260 | CHU de Quebec-Universite Laval | EARLY_Phase 1 |
| Completed | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumor NCT04853017 | Elicio Therapeutics | Phase 1 |
| Recruiting | Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer NCT04969731 | GC Cell Corporation | Phase 3 |
| Recruiting | Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer NCT04927780 | Erasmus Medical Center | Phase 3 |
| Unknown | Peri-operative SLOG for Localized Pancreatic Cancer NCT05048524 | National Health Research Institutes, Taiwan | Phase 2 |
| Active Not Recruiting | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelima NCT04827953 | Nelum Corp | Phase 1 / Phase 2 |
| Recruiting | A Prospective Registry for Patients at High-Risk for Pancreatic Cancer NCT06151223 | Mayo Clinic | — |
| Withdrawn | PanDox: Targeted Doxorubicin in Pancreatic Tumours NCT04852367 | University of Oxford | Phase 1 |
| Completed | Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma NCT04662112 | Asan Medical Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Mal NCT04913337 | NGM Biopharmaceuticals, Inc | Phase 1 / Phase 2 |
| Recruiting | AB122 Platform Study NCT04999761 | Taiho Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatme NCT04752696 | Cardiff Oncology | Phase 2 |
| Completed | Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer NCT04634539 | Jun Gong, MD | Phase 1 |
| Active Not Recruiting | OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDA NCT03806309 | GERCOR - Multidisciplinary Oncology Cooperative Group | Phase 2 |
| Terminated | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab NCT04779151 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Withdrawn | Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent 111In-IPN01087 in Patien NCT04632199 | Ipsen | Phase 1 |
| Completed | A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP NCT04740164 | M.D. Anderson Cancer Center | N/A |
| Completed | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors NCT04580485 | Incyte Corporation | Phase 1 |
| Completed | A Combination of AKR1B10 and CA19-9 Improves the Diagnosis of PDAC NCT04726956 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors NCT04657068 | Artios Pharma Ltd | Phase 1 / Phase 2 |
| Recruiting | iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation NCT03608631 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Effects of Different Methods of PDAC Specimen Acquisition on Primary Cell Culture and Application NCT04797676 | The Third Xiangya Hospital of Central South University | — |
| Unknown | A Clinical Study to Evaluated Which Number of Passes of EUS-FNB is Better for Culturing Primary Cells of PDAC NCT04794140 | The Third Xiangya Hospital of Central South University | N/A |
| Recruiting | SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells NCT04150042 | General Oncology, Inc. | Phase 1 |
| Withdrawn | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Ad NCT04262388 | University Health Network, Toronto | Phase 2 |
| Unknown | Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) NCT04692740 | Michele Reni | Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Thera NCT04477343 | University of Rochester | Phase 1 |
| Active Not Recruiting | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma NCT04111172 | Thomas Jefferson University | Phase 2 |
| Completed | Pancreatic Adenocarcinoma Signature Stratification for Treatment NCT04469556 | University Health Network, Toronto | Phase 2 |
| Completed | Recurrence After Whipple's (RAW) Study NCT04596865 | University Hospital Plymouth NHS Trust | — |
| Terminated | Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer NCT04400903 | OHSU Knight Cancer Institute | — |
| Recruiting | Pancreatic Cancer Early Detection Consortium NCT04970056 | Arbor Research Collaborative for Health | — |
| Terminated | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma NCT04565327 | Zhen Wang, MD | Phase 2 |
| Unknown | Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA) NCT04483726 | University Hospital, Montpellier | N/A |
| Unknown | PAXG Out in the Country NCT04480268 | IRCCS San Raffaele | Phase 4 |
| Completed | Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suff NCT04257448 | GWT-TUD GmbH | Phase 1 / Phase 2 |
| Withdrawn | Novel MRI Techniques for Pancreatic Cancer NCT04306861 | Beth Israel Deaconess Medical Center | — |
| Completed | EUS-RFA for Unresectable Pancreatic Cancer NCT04310111 | First People's Hospital of Hangzhou | N/A |
| Completed | Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma NCT05048810 | Nanjing First Hospital, Nanjing Medical University | N/A |
| Active Not Recruiting | Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers NCT04449406 | Queen Mary University of London | — |
| Unknown | Microbiome Analysis in esoPhageal, PancreatIc and Colorectal CaNcer Patients Undergoing Gastrointestinal Surge NCT04189393 | Radboud University Medical Center | — |
| Withdrawn | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma NCT04134468 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreati NCT03767582 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Unknown | Endoscopic Ultrasound Radiofrequency Ablation (EUS-RFA) of Not-resectable Pancreatic Cancer NCT04164992 | Campus Bio-Medico University | N/A |
| Terminated | Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma NCT03979066 | Gulam Manji | Phase 2 |
| Terminated | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers NCT04025216 | Kite, A Gilead Company | Phase 1 |
| Recruiting | UCSF PANC Cyst Registry NCT04291651 | University of California, San Francisco | — |
| Terminated | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) NCT04046887 | Patrick Joseph Loehrer Sr. | Phase 1 |
| Terminated | A Study of SGN-CD228A in Advanced Solid Tumors NCT04042480 | Seagen Inc. | Phase 1 |
| Unknown | Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program NCT03865875 | Massachusetts General Hospital | N/A |
| Withdrawn | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer NCT03432676 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma NCT03915444 | HonorHealth Research Institute | Phase 2 |
| Completed | Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatme NCT03727880 | Lei Zheng | Phase 2 |
| Withdrawn | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) NCT03697239 | Hitendra Patel | Phase 1 / Phase 2 |
| Unknown | Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management St NCT03951324 | Innovative Digestive Health Education and Research Inc | — |
| Withdrawn | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) NCT03908333 | Medical College of Wisconsin | Phase 1 / Phase 2 |
| Unknown | Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC NCT03634332 | Pancreatic Cancer Research Team | Phase 2 |
| Terminated | A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocar NCT03890198 | First Affiliated Hospital Xi'an Jiaotong University | EARLY_Phase 1 |
| Unknown | Clinical Study Between Robotic and Open Surgery in Patients With Pancreatic Cancer NCT04211948 | Ruijin Hospital | N/A |
| Terminated | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images NCT03852836 | IHU Strasbourg | N/A |
| Suspended | A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma NCT03444948 | Centre hospitalier de l'Université de Montréal (CHUM) | N/A |
| Active Not Recruiting | High Resolution Ultrasound in Pancreatic Ductal Adenocarcinoma NCT03820661 | University Health Network, Toronto | N/A |
| Completed | CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy NCT03851237 | Washington University School of Medicine | Phase 1 |
| Completed | DC Vaccine in Pancreatic Cancer NCT03592888 | University of Pennsylvania | Phase 1 |
| Completed | Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy f NCT03770117 | Manchester University NHS Foundation Trust | — |
| Completed | BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pan NCT03496662 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Withdrawn | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer NCT03374852 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer NCT03517176 | Lisata Therapeutics, Inc. | Phase 1 |
| Completed | A Study of Personalized Neoantigen Cancer Vaccines NCT03794128 | Gritstone bio, Inc. | — |
| Terminated | Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions NCT03486327 | Bracco Diagnostics, Inc | Phase 2 |
| Completed | Impact of Multidisciplinary and Radiologic Review on Outcome of Pancreatic Cancer Patients: an Observational S NCT03973736 | Azienda USL Reggio Emilia - IRCCS | — |
| Unknown | Should a Standard Lymphadenectomy Include the No. 16 Lymph Nodes for Patients With Pancreatic Head Adenocarcin NCT04115527 | Ruijin Hospital | N/A |
| Terminated | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tum NCT03525392 | Ipsen | Phase 1 |
| Unknown | Comparing Total Laparoscopic Versus Open Pancreaticoduodenectomy NCT03138213 | Tongji Hospital | N/A |
| Unknown | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic NCT01676259 | Silenseed Ltd | Phase 2 |
| Unknown | Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms NCT03435770 | Singapore General Hospital | N/A |
| Completed | Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPL NCT03415854 | HonorHealth Research Institute | Phase 2 |
| Terminated | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer NCT03481920 | PH Research, S.L. | EARLY_Phase 1 |
| Completed | Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) NCT03410030 | HonorHealth Research Institute | Phase 1 / Phase 2 |
| Unknown | Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer NCT03317886 | Wakayama Medical University | Phase 3 |
| Completed | IACS-010759 in Advanced Cancers NCT03291938 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer NCT03316326 | National Taiwan University Hospital | Phase 2 |
| Completed | A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer NCT03257150 | University Health Network, Toronto | N/A |
| Completed | A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors NCT03267316 | Cantargia AB | Phase 1 / Phase 2 |
| Unknown | PEN-866 in Patients With Advanced Solid Malignancies NCT03221400 | Tarveda Therapeutics | Phase 1 / Phase 2 |
| Terminated | CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer NCT03012282 | University of Washington | N/A |
| Unknown | A Study Evaluating MM-310 in Patients With Solid Tumors NCT03076372 | Merrimack Pharmaceuticals | Phase 1 |
| Completed | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously T NCT02981342 | Eli Lilly and Company | Phase 2 |
| Unknown | Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases Aft NCT03687853 | Peking University Third Hospital | N/A |
| Completed | Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma NCT02959164 | Mohammed Milhem | Phase 1 |
| Completed | Olaparib in Treating Patients With Stage IV Pancreatic Cancer NCT02677038 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors NCT02607826 | University Hospital Tuebingen | N/A |
| Unknown | Study of NAC of GA Therapy for Patients With BRPC NCT02926183 | Wakayama Medical University | Phase 2 |
| Active Not Recruiting | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors NCT02498613 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer NCT02929797 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | EARLY_Phase 1 |
| Completed | Lymphadenectomy for Pancreatic Head Cancer: Standard or Extended? NCT02787187 | Ruijin Hospital | N/A |
| Completed | Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer NCT02790944 | Ambry Genetics | — |
| Recruiting | High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer Tha NCT02757859 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | N/A |
| Completed | NGS and TME for Evidence-based Treatment of Pancreatic Cancer NCT02767700 | Karolinska University Hospital | — |
| Completed | A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups NCT03693378 | Immunovia, Inc. | — |
| Completed | Study of Tremelimumab in Patients With Advanced Solid Tumors NCT02527434 | AstraZeneca | Phase 2 |
| Withdrawn | Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Ca NCT02570529 | Yonsei University | Phase 4 |
| Completed | Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial NCT02440958 | Yonsei University | Phase 2 |
| Completed | Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma NCT02426281 | Samsung Medical Center | Phase 2 |
| Recruiting | The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer NCT04406831 | Nuvance Health | — |
| Completed | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal NCT02259114 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Terminated | Plasma Biomarkers P-DAC, V1 NCT02050997 | Cancer Trials Ireland | — |
| Completed | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation NCT02042378 | pharmaand GmbH | Phase 2 |
| Withdrawn | A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients Wit NCT01911416 | University of Utah | N/A |
| Unknown | Pancreatic Cancer Recurrence in the Netherlands NCT04605237 | UMC Utrecht | — |
| Withdrawn | Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancr NCT02414100 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | — |
| Unknown | Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial] NCT01879878 | Heidelberg University | N/A |
| Active Not Recruiting | A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma NCT01983410 | Memorial Sloan Kettering Cancer Center | — |
| Terminated | Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer NCT01962909 | University of Virginia | EARLY_Phase 1 |
| Unknown | Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas NCT01942629 | Rambam Health Care Campus | — |
| Unknown | Differentiating Tumor-stroma Ratio in Pancreatic Ductal Adenocarcinoma NCT06302881 | First Affiliated Hospital of Chongqing Medical University | — |
| Completed | Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Pa NCT01658943 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Canc NCT01580397 | ImmunityBio, Inc. | Phase 2 |
| Terminated | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarc NCT01431794 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Terminated | Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS) NCT01096732 | Lisa Bax | Phase 2 |
| Completed | Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocar NCT01188785 | Silenseed Ltd | Phase 1 |
| Completed | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pan NCT01280058 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen Wi NCT01013649 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery NCT00669734 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Survival Among Patients With Pancreatic Cancer Depending on Surgical Resection Rate NCT04802993 | Linkoeping University | — |
| Completed | Radiomics Based on Multimodal Imaging in Predicting Staging and Prognosis of Pancreatic Cancer NCT04954378 | Peking University Third Hospital | — |
| Completed | Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer NCT01547260 | Maria Liljefors | Phase 1 / Phase 2 |
| Active Not Recruiting | GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metas NCT00878163 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine NCT00307723 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Completed | CT Pancreas Perfusion NCT00588367 | Mayo Clinic | — |
| Withdrawn | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic P NCT02575508 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Available | Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma NCT07083479 | Elicio Therapeutics | — |